Triple combination therapy kills glioblastoma in mice by putting an “eat me” signal to the immune system on the surface of the brain tumor cells, blocking an offsetting “don’t eat me” signal and protecting a cancer-killing immune response launched by the combination.
The brain tumor treatment, as reported in Nature Communications, more than doubled median survival of mice treated with all three drugs, compared to those treated...
Combining two immunotherapies caused tumor rejection in mouse models of pancreatic cancer and provided long-term immune memory that prevented...
Surveying the landscape of T cell presence and activity across the lungs of patients treated for localized non-small cell lung cancer, researchers...
President Donald Trump today announced his intent to appoint Hussein Tawbi, M.D., Ph.D., associate professor and deputy chairman of Melanoma Medical Oncology, to the President’s Council of Advisors on Science and Technology, known as PCAST.
PCAST, composed of the director of the Office of Science and Technology and up to 16 additional members appointed by the president, advises the president on matters involving science, technology...
An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different...
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...
Small precancerous growths in the lungs are capable of progressing to invasive lung cancer, but so little has been known about them that understanding...
Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...
A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer...
Combining two types of drugs that, separately, have extended the lives of people with metastatic melanoma has yielded higher response rates...